Shopping Cart 0
Cart Subtotal
USD 0

Daiichi Sankyo Co Ltd (4568) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Daiichi Sankyo Company Ltd (Daiichi Sankyo) is a holding company that carries out the research, development, manufacture, and marketing of pharmaceutical products. The company offers a wide range of prescription drugs, over-the-counter (OTC) drugs, vaccines, and others. Its portfolio encompasses medicines for cardiovascular, neurological, nephrologic, diabetic, metabolic and infectious diseases; and various types of cancers. Daiichi Sankyo sells its products through its group companies, and an extensive network of medical representatives. It has operations in North America, South and Central America, Europe and Asia. Daiichi Sankyo is headquartered in Tokyo, Japan.

Daiichi Sankyo Co Ltd (4568)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 8

List of Figures 9

Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 11

Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 12

Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 13

Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 14

Daiichi Sankyo Co Ltd, Medical Devices Deals, 2012 to YTD 2018 16

Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 17

Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deal Details 23

Venture Financing 23

Ambit Biosciences Raises USD 25 Million In First Tranche Of Venture Financing 23

Ambit Biosciences Raises USD 7.07 Million In Venture Financing 25

Partnerships 26

Daiichi Sankyo Enters into Research Collaboration with Merck and Pfizer 26

Daiichi Sankyo Enters into Co-Development Agreement with Merck Sharp & Dohme 27

PhoreMost Enters into Collaboration Agreement with Plexxikon 28

Daiichi Sankyo Enters into Agreement with DarwinHealth 29

Evotec Enters into Agreement with U3 Pharma 30

Vernalis and Daiichi Sankyo Enter into Agreement 31

Daiichi Sankyo and Puma Biotech Enter into Research Agreement with Memorial Sloan Kettering Cancer Center 32

Daiichi Sankyo and Glycotope Enter into Option Agreement 33

Daiichi Sankyo Partners with Saitama Medical University 34

National Cancer Center, JVCKENWOOD, Sysmex and Daiichi Sankyo Enter into Agreement 35

University of Texas MD Anderson and Daiichi Sankyo Enter into Research Agreement 36

Bristol-Myers Squibb and Daiichi Sankyo Enter into Agreement 37

Daiichi Sankyo Enters into Agreement with Kyukyu Pharma 38

Daiichi Sankyo, Max Planck Innovation and Lead Discovery Center Enter into Research Agreement 39

ProLynx Enters into Partnership with Daiichi Sankyo 40

Daiichi Sankyo Enters into Research Agreement with Drugs for Neglected Diseases initiative 41

National Institutes of Biomedical Innovation, Daiichi Sankyo and Mitsubishi UFJ Capital Form Joint Venture 42

Daiichi Sankyo Enters into Research Agreement with Dana-Farber Cancer Institute 43

Daiichi Sankyo Enters into Research Agreement with Medicines for Malaria Venture 44

Daiichi Sankyo Enters into Research Agreement with AgonOx 45

Amgen and Daiichi Sankyo Enter into Agreement 46

Daiichi Sankyo Enters Into Marketing Agreement With Servier Canada 47

Astellas Pharm, Kyowa Hakko Kirin, Daiichi Sankyo, Eisai, Ono Pharma and Chugai Pharma to Enter into Agreemet with Four Research Institutions 48

Astellas Pharma, Daiichi Sankyo and Takeda Pharma Enter into Research Agreement 50

Asahikawa Medical University, Daiichi Sankyo and Mitsubishi UFJ Capital Form Joint Venture 51

Daiichi Sankyo Enters into Co-Marketing Agreement with Merck 52

Daiichi Sankyo Enters into Co-Marketing Agreement with Daewoong Pharma 53

Simcere Pharma Enters into Agreement with Daiichi Sankyo 54

Daiichi Sankyo, Japan Vaccine and Sanofi Enter into Co-Marketing Agreement 55

Daiichi Sankyo Partners with Cytoo 56

Biohit Enters into Distribution Agreement with Daiichi Sankyo 57

Daiichi Sankyo Enters into Agreement with Maruishi Pharma 58

Plexxikon Enters into Agreement with Merck 59

AstraZeneca Enters into Commercialization Agreement with Daiichi Sankyo for Movantik 60

Daiichi Sankyo Enters into Co-Marketing Agreement with UCB Biopharma for Lacosamide 61

Portola Pharma Enters into Expanded Agreement with Daiichi Sankyo 62

Sanford Burnham Enters into Co-Development Agreement with Daiichi Sankyo 63

MRC Technology Enters into Drug Discovery Agreement with Daiichi Sankyo 64

Agendia Enters into Co-Development Agreement with Daiichi Sankyo 65

Daiichi Sankyo Enters into Co-Promotion Agreement with Daewoong Pharma For Olostar 66

Daiichi Sankyo Enters Into Drug Discovery Agreement With Lead Discovery Center 67

Daiichi Sankyo Enters Into Co-Development Agreement With UCSF 68

Daiichi Sankyo and UMN Pharma Enter into Research Agreement for Norovirus Vaccine 69

Abcheck Enters Into Research Agreement With U3 Pharma 70

Daiichi Sankyo Forms Joint Venture With Innovation Network Corporation And Mitsubishi UFJ Capital 71

Daiichi Sankyo Enters Into Agreement With Amplimmune To Develop Therapy For Autoimmune Disease 72

PeptiDream Enters into Drug Discovery Agreement with Daiichi Sankyo 73

Daiichi Sankyo Venezuela Enters Into Co-Marketing Agreement With Ranbaxy Labs 74

Daiichi Sankyo Enters Into Co-Development Agreement With National Cancer Center Hospital East 75

Daiichi Sankyo Enters Into Co-Marketing Agreement With Terapia Ranbaxy For Sevikar 76

Daiichi Sankyo Enters Into Co-Development Agreement With NGM Biopharma For Diabetes Drugs 77

Mitsubishi Tanabe Pharma Expands its Co-Marketing Agreement with Daiichi Sankyo for MP-513 And TA-7284 78

Daiichi Sankyo And GlaxoSmithKline to Dissolve Joint Venture 79

Daiichi Sankyo Enters Into Co-Development Agreement With Terumo For Intradermal Vaccine 80

Merger 81

Daiichi Sankyo to Merge with Asubio Pharma 81

Licensing Agreements 82

Daiichi Sankyo Enters into Licensing Agreement with Glycotope 82

Menarini Enters into Licensing Agreement with Daiichi Sankyo 83

Daiichi Sankyo Enters into Licensing Agreement with Zymeworks 84

Daiichi Sankyo Enters into Licensing Agreement with Boston Pharma 85

Daiichi Sankyo to Enter into Licensing Agreement with Inspirion Delivery Sciences 86

Daiichi Sankyo Enters into Licensing Agreement with Sosei Group 87

Daiichi Sankyo Enters into Licensing Agreement with Heptares Therapeutics 88

Daiichi Sankyo Enters into Licensing Agreement with Kite Pharma 89

Daiichi Sankyo Enters into Licensing Agreement with Inspirion Delivery Sciences 90

Daiichi Sankyo Enters into Licensing Agreement with Zymeworks 91

Zymeworks Enters into Licensing Agreement with Daiichi Sankyo 92

Daiichi Sankyo Enters into Licensing Agreement with Cell Therapy 93

Daiichi Sankyo Enters into Licensing Agreement with MedImmune for FluMist 94

Dainippon Sumitomo Pharma Enters into Licensing Agreement with Daiichi Sankyo 95

Odonate Therapeutics Enters Into Licensing Agreement With Daiichi Sankyo 96

Affibody Enters Into Licensing Agreement With Daiichi Sankyo For Albumod 97

Equity Offering 98

Daiichi Sankyo Invests in Cuorips 98

Daiichi Sankyo to Invest in USD196.7 Million in Luitpold Pharma 99

Daiichi Sankyo Raises USD3.6 Billion in Public Offering of Shares of Sun Pharma 100

Ambit Biosciences Completes Private Placement Of Shares For USD 25 Million 101

Ambit Biosciences Completes IPO Of Shares For USD 65 Million 102

Debt Offering 104

Daiichi Sankyo to Raise USD713.4 Million in Public Offering of 0.81% 5th Series Bonds Due 2036 104

Daiichi Sankyo to Raise USD237.8 Million in Public Offering of 1.2% 6th Series Bonds Due 2046 105

Asset Transactions 106

Alfresa Pharma to Acquire 41 Products from Daiichi Sankyo 106

Amring Pharma Acquires Six ANDAs from Luitpold Pharma and AlphaForce 107

Egalet Acquires SPRIX Nasal Spray from Luitpold Pharma 108

CMIC CMO Completes Acquisition Of Research Equipment From Daiichi Sankyo 110

Acquisition 111

Sun Pharma Acquires Ranbaxy Labs for USD4 Billion 111

Daiichi Sankyo Acquires Majority Stake in Ambit Biosciences 114

Daiichi Sankyo Acquires Shanghai Xinshengyuan Pharma From Xinshengyuan Pharma 116

Daiichi Sankyo Plans To Acquire India-Based Pharma Company 117

Daiichi Sankyo Co Ltd-Key Competitors 118

Daiichi Sankyo Co Ltd-Key Employees 119

Daiichi Sankyo Co Ltd-Locations And Subsidiaries 121

Head Office 121

Other Locations & Subsidiaries 121

Joint Venture 124

Recent Developments 125

Strategy And Business Planning 125

Aug 01, 2018: Daiichi Sankyo transfers 41 products to Alfresa Pharma 125

Apr 27, 2018: Daiichi Sankyo to Reorganize Kitasato Daiichi Sankyo Vaccine into Specialized Manufacturing Subsidiary 126

Feb 23, 2018: Daiichi Sankyo Announces Organizational Restructuring Effective as of April 1, 2018 127

Jan 09, 2018: Daiichi Sankyo to Convert Kitasato Daiichi Sankyo Vaccine into Wholly Owned Subsidiary 129

Sep 07, 2017: Daiichi Sankyo Announces Organizational Restructuring Effective as of October 1, 2017 130

Feb 24, 2017: Daiichi Sankyo Announces Organizational Restructuring Effective as of April 1, 2017 131

Feb 15, 2017: Daiichi Sankyo Strengthens Authorized Generic Business through Daiichi Sankyo Espha 133

Feb 10, 2017: Daiichi Sankyo Announces Further Reorganization of its Research & Development Structure 135

Corporate Communications 136

May 11, 2018: Daiichi Sankyo Announces Changes to Representative Directors and Members of the Audit and Supervisory Board 136

Jan 31, 2017: Daiichi Sankyo Announces New Chairman and President 137

Legal and Regulatory 138

Jun 06, 2018: Daiichi Sankyo's U.S. Products Liability Litigation Settlement Program Moves Forward; More than 97 Percent of Eligible Litigants and Claimants Opt In 138

Mar 30, 2018: Daiichi Sankyo Agrees to Modify the Terms of the Settlement Program for U.S. Olmesartan Products Liability Litigation 139

Aug 01, 2017: Daiichi Sankyo Announces Settlement Agreement on U.S. Products Liability Litigation 140

Government and Public Interest 141

Jul 11, 2017: Daiichi Sankyo Selected for Ninth Consecutive Year as Constituent of FTSE4Good Global Index by FTSE Russell 141

Jul 03, 2017: 15th Takamine Memorial Daiichi Sankyo Prize Winner Announced 142

Jun 16, 2017: Daiichi Sankyos Japan Research Foundation for Clinical Pharmacology 10th Annual Clinical Pharmacology Research Award 143

Jan 18, 2017: Daiichi Sankyo Announces Participation in the Global Initiative, Access Accelerated 144

Product News 145

Oct 12, 2017: Daiichi Sankyo Announces Support from the Japan Agency for Medical Research and Developments CiCLE Program for Its Genetic Vaccine Platform, and Commencement of an Industry- Government-Academia Research & Development Collaboration for Development Vaccines Using the Platform 145

Oct 11, 2017: Astellas, Mitsubishi Tanabe Pharma, and Daiichi Sankyo Conduct JOINUS, a New Drug Discovery Program Using Drug-Repositioning Compound Library 146

09/03/2018: The FDA attributed the designation of innovative therapy to quizartinib, a FLT3 inhibitor for the treatment of relapsed / refractory AML from Daiichi Sankyo 147

08/30/2017: "Tazopipe Notice of additional adaptation acquisition of the blending static for the Note" Meiji 148

Aug 29, 2018: ProLynx and Daiichi Sankyo announce the development of technology for half-life extension of small molecules in the eye 149

08/29/2017: FDA Grants Breakthrough Therapy Designation to Daiichi Sankyos DS-8201 for HER2-Positive Metastatic Breast Cancer 150

08/01/2018: Daiichi Sankyo announce FDA grants breakthrough therapy designation to Daiichi Sankyos FLT3 inhibitor Quizartinib for relapsed/refractory FLT3-ITD AML 151

Jul 20, 2017: Daiichi Sankyo Opens Applications for Investigator-Initiated Studies Program 152

Jun 15, 2017: Daiichi Sankyo Launches New Generic Drugs through Its Daiichi Sankyo Espha Subsidiary 153

04/20/2018: Vaxart Announces $5 Million Inavir Revenue Milestone 156

Mar 30, 2017: Daiichi Sankyo Announces Collaborative Research on Drugs for Neglected Tropical Diseases 157

03/26/2018: Japanese Government to Stockpile Inavir Anti-influenza Drug for Combatting Pandemic Influenza Threats in Japan 158

Mar 16, 2017: The National Institutes of Biomedical Innovation, Health and Nutrition, Daiichi Sankyo,and Mitsubishi UFJ Capital Announce Open Innovation Research on New Cancer Immunotherapy 159

01/18/2017: - lactamase inhibitor formulated antibiotic formulation "Tazopipe Notice of additional indications and effect the acquisition of blending static for the Note" Meiji "" 160

01/18/2017: Daiichi Sankyo Initiates Phase 1/2 Study of Novel Antibody Drug Conjugate U3-1402 in Patients with HER3-Positive Metastatic or Unresectable Breast Cancer 161

Product Approvals 162

Feb 15, 2018: Daiichi Sankyo Submits Marketing Application for Mirogabalin in Japan 162

Clinical Trials 163

Jul 06, 2018: Northwestern University: Clinical Trial Show Promise in Leukemia 163

Jun 16, 2018: Phase 3 QuANTUM-R Study Demonstrates Daiichi Sankyos Quizartinib Significantly Prolongs Overall Survival as Single Agent Compared to Chemotherapy in Patients with Relapsed/Refractory AML with FLT3-ITD Mutations 164

Jun 12, 2018: EHA Late-Breaking, Plenary Presentation: Quizartinib Significantly Prolongs Overall Survival in Pivotal, Phase 3 AML Study 166

Jun 06, 2018: Daiichi Sankyo to Present Late-Breaking Phase 3 Data for Single Agent Quizartinib in Patients with Relapsed/Refractory AML with FLT3-ITD Mutations at Plenary Session at EHA 2018 167

May 08, 2018: Daiichi Sankyo Announces Single Agent Quizartinib Significantly Prolongs Overall Survival Compared with Chemotherapy in Patients with Relapsed/Refractory AML with FLT3-ITD Mutations (QuANTUM-R Study) 169

Dec 28, 2017: Odonate Therapeutics Announces Initiation of CONTESSA, a Phase 3 Study of Tesetaxel in Patients with Locally Advanced or Metastatic Breast Cancer 170

Dec 22, 2017: Glycotope Initiates Phase Ib Trial of Combination of Proprietary Anti-Tumor Antibodies 172

Dec 11, 2017: Daiichi Sankyo Presents Phase 1 Data for EZH1/2 Dual Inhibitor DS-3201 in Patients with Non-Hodgkin Lymphomas at the 59th Annual Meeting of the American Society of Hematology 173

Dec 07, 2017: Daiichi Sankyo Presents Updated Data for DS-8201 in Patients with HER2-Expressing Breast Cancer at San Antonio Breast Cancer Symposium 175

Nov 20, 2017: Daiichi Sankyo Initiates Pivotal Phase 2 Study of DS-8201 in Patients with HER2-Positive Advanced Gastric Cancer 176

Nov 14, 2017: Daiichi Sankyo Announces Presentation on its Investigational Agent DS-3201 at ASH 178

Nov 14, 2017: Daiichi Sankyo Announces Presentation on its Investigational Agent Quizartinib dihydrochloride at ASH 179

Nov 14, 2017: Daiichi Sankyo to Present Updated DS-8201 Data at SABCS 180

Sep 11, 2017: Daiichi Sankyo Presents New Data for DS-8201 in Multiple HER2-Expressing Solid Tumors at European Society for Medical Oncology (ESMO) 2017 Congress 181

Sep 06, 2017: Sanford Burnham Prebys and Daiichi Sankyo Announce Enrollment of First Subject in a Phase 1 Clinical Trial of DS-1211 in Healthy Volunteers 183

Aug 31, 2017: Daiichi Sankyo Announces Positive Top-line Results from Phase 3 Clinical Trial Evaluating Mirogabalin in Diabetic Peripheral Neuropathic Pain 184

Aug 31, 2017: Daiichi Sankyo Presents Data on DS-1205 at the European Society for Medical Oncology 2017 Congress 185

Aug 31, 2017: Daiichi Sankyo Showcases New Insights on DS-8201 at the European Society for Medical Oncology 2017 Congress 186

Aug 31, 2017: Daiichi Sankyo to Present Data on leukemia Drug Candidate Quizartinib at the European Society for Medical Oncology 2017 Congress 187

Aug 29, 2017: Daiichi Sankyo Initiates Pivotal Phase 2 Study of DS-8201 in Patients with HER2-Positive Metastatic Breast Cancer 188

Jun 30, 2017: Daiichi Sankyo Announces Top-line Results from Phase 3 Global Clinical Development Program Evaluating Mirogabalin in Pain Syndromes 189

Jun 05, 2017: New Precision Medicine Data on DS-8201 in HER2-Expressing Breast Cancer Revealed at 2017 American Society of Clinical Oncology (ASCO) Annual Meeting 191

Mar 29, 2017: Daiichi Sankyo Cancer Enterprise Showcases New Data on DS-8201 at American Association for Cancer Research 2017 Annual Meeting 193

Mar 29, 2017: Daiichi Sankyo Cancer Enterprise Showcases New Data on U3-1402 at American Association for Cancer Research 2017 Annual Meeting 194

Mar 29, 2017: Daiichi Sankyo Showcases New Data on EZH1/2 Inhibition at American Association for Cancer Research 2017 Annual Meeting 195

Other Significant Developments 196

Oct 09, 2018: Astellas, Mitsubishi Tanabe Pharma, and Daiichi Sankyo announce second public recruitment offering of "Joinus", a joint research program to discover new drugs using drug-repositioning compound library 196

Feb 28, 2018: Daiichi Sankyo Aligns U.S. Commercial Operations to Current Portfolio and Upcoming Cancer Pipeline 197

Oct 30, 2017: Daiichi Sankyo Working with Berkeley Lights' Beacon OptoFluidic Platform for Cell Line Development 198

Sep 26, 2017: Daiichi Sankyo Announces TaNeDS Global 2018 Collaborative Drug Discovery Program 199

Apr 27, 2017: Daiichi Sankyo Announces 15 Billion Yen Manufacturing Investment to Support Acceleration of Antibody Drug Conjugate Portfolio 201

Mar 23, 2017: Daiichi Sankyo to Facilitate New Drug Discovery in 2017 through Collaborative Research and Grants 202

Feb 14, 2017: PeptiDream Announces the Selection of Development Candidate from Discovery Collaboration with Daiichi Sankyo 203

Feb 02, 2017: Daiichi Sankyo Announces Continuation of Mobile Healthcare Field Clinic Service Aimed at Improving Healthcare Access in Tanzania 204

Jan 10, 2017: Daiichi Sankyo Announces Reorganization of Research & Development System 205

Appendix 206

Methodology 206

About GlobalData 206

Contact Us 206

Disclaimer 206


List Of Figure

List of Figures

Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 11

Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 12

Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 13

Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 14

Daiichi Sankyo Co Ltd, Medical Devices Deals, 2012 to YTD 2018 16


List Of Table

List of Tables

Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 11

Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 12

Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 13

Daiichi Sankyo Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 14

Daiichi Sankyo Co Ltd, Medical Devices Deals, 2012 to YTD 2018 16

Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 17

Ambit Biosciences Raises USD 25 Million In First Tranche Of Venture Financing 23

Ambit Biosciences Raises USD 7.07 Million In Venture Financing 25

Daiichi Sankyo Enters into Research Collaboration with Merck and Pfizer 26

Daiichi Sankyo Enters into Co-Development Agreement with Merck Sharp & Dohme 27

PhoreMost Enters into Collaboration Agreement with Plexxikon 28

Daiichi Sankyo Enters into Agreement with DarwinHealth 29

Evotec Enters into Agreement with U3 Pharma 30

Vernalis and Daiichi Sankyo Enter into Agreement 31

Daiichi Sankyo and Puma Biotech Enter into Research Agreement with Memorial Sloan Kettering Cancer Center 32

Daiichi Sankyo and Glycotope Enter into Option Agreement 33

Daiichi Sankyo Partners with Saitama Medical University 34

National Cancer Center, JVCKENWOOD, Sysmex and Daiichi Sankyo Enter into Agreement 35

University of Texas MD Anderson and Daiichi Sankyo Enter into Research Agreement 36

Bristol-Myers Squibb and Daiichi Sankyo Enter into Agreement 37

Daiichi Sankyo Enters into Agreement with Kyukyu Pharma 38

Daiichi Sankyo, Max Planck Innovation and Lead Discovery Center Enter into Research Agreement 39

ProLynx Enters into Partnership with Daiichi Sankyo 40

Daiichi Sankyo Enters into Research Agreement with Drugs for Neglected Diseases initiative 41

National Institutes of Biomedical Innovation, Daiichi Sankyo and Mitsubishi UFJ Capital Form Joint Venture 42

Daiichi Sankyo Enters into Research Agreement with Dana-Farber Cancer Institute 43

Daiichi Sankyo Enters into Research Agreement with Medicines for Malaria Venture 44

Daiichi Sankyo Enters into Research Agreement with AgonOx 45

Amgen and Daiichi Sankyo Enter into Agreement 46

Daiichi Sankyo Enters Into Marketing Agreement With Servier Canada 47

Astellas Pharm, Kyowa Hakko Kirin, Daiichi Sankyo, Eisai, Ono Pharma and Chugai Pharma to Enter into Agreemet with Four Research Institutions 48

Astellas Pharma, Daiichi Sankyo and Takeda Pharma Enter into Research Agreement 50

Asahikawa Medical University, Daiichi Sankyo and Mitsubishi UFJ Capital Form Joint Venture 51

Daiichi Sankyo Enters into Co-Marketing Agreement with Merck 52

Daiichi Sankyo Enters into Co-Marketing Agreement with Daewoong Pharma 53

Simcere Pharma Enters into Agreement with Daiichi Sankyo 54

Daiichi Sankyo, Japan Vaccine and Sanofi Enter into Co-Marketing Agreement 55

Daiichi Sankyo Partners with Cytoo 56

Biohit Enters into Distribution Agreement with Daiichi Sankyo 57

Daiichi Sankyo Enters into Agreement with Maruishi Pharma 58

Plexxikon Enters into Agreement with Merck 59

AstraZeneca Enters into Commercialization Agreement with Daiichi Sankyo for Movantik 60

Daiichi Sankyo Enters into Co-Marketing Agreement with UCB Biopharma for Lacosamide 61

Portola Pharma Enters into Expanded Agreement with Daiichi Sankyo 62

Sanford Burnham Enters into Co-Development Agreement with Daiichi Sankyo 63

MRC Technology Enters into Drug Discovery Agreement with Daiichi Sankyo 64

Agendia Enters into Co-Development Agreement with Daiichi Sankyo 65

Daiichi Sankyo Enters into Co-Promotion Agreement with Daewoong Pharma For Olostar 66

Daiichi Sankyo Enters Into Drug Discovery Agreement With Lead Discovery Center 67

Daiichi Sankyo Enters Into Co-Development Agreement With UCSF 68

Daiichi Sankyo and UMN Pharma Enter into Research Agreement for Norovirus Vaccine 69

Abcheck Enters Into Research Agreement With U3 Pharma 70

Daiichi Sankyo Forms Joint Venture With Innovation Network Corporation And Mitsubishi UFJ Capital 71

Daiichi Sankyo Enters Into Agreement With Amplimmune To Develop Therapy For Autoimmune Disease 72

PeptiDream Enters into Drug Discovery Agreement with Daiichi Sankyo 73

Daiichi Sankyo Venezuela Enters Into Co-Marketing Agreement With Ranbaxy Labs 74

Daiichi Sankyo Enters Into Co-Development Agreement With National Cancer Center Hospital East 75

Daiichi Sankyo Enters Into Co-Marketing Agreement With Terapia Ranbaxy For Sevikar 76

Daiichi Sankyo Enters Into Co-Development Agreement With NGM Biopharma For Diabetes Drugs 77

Mitsubishi Tanabe Pharma Expands its Co-Marketing Agreement with Daiichi Sankyo for MP-513 And TA-7284 78

Daiichi Sankyo And GlaxoSmithKline to Dissolve Joint Venture 79

Daiichi Sankyo Enters Into Co-Development Agreement With Terumo For Intradermal Vaccine 80

Daiichi Sankyo to Merge with Asubio Pharma 81

Daiichi Sankyo Enters into Licensing Agreement with Glycotope 82

Menarini Enters into Licensing Agreement with Daiichi Sankyo 83

Daiichi Sankyo Enters into Licensing Agreement with Zymeworks 84

Daiichi Sankyo Enters into Licensing Agreement with Boston Pharma 85

Daiichi Sankyo to Enter into Licensing Agreement with Inspirion Delivery Sciences 86

Daiichi Sankyo Enters into Licensing Agreement with Sosei Group 87

Daiichi Sankyo Enters into Licensing Agreement with Heptares Therapeutics 88

Daiichi Sankyo Enters into Licensing Agreement with Kite Pharma 89

Daiichi Sankyo Enters into Licensing Agreement with Inspirion Delivery Sciences 90

Daiichi Sankyo Enters into Licensing Agreement with Zymeworks 91

Zymeworks Enters into Licensing Agreement with Daiichi Sankyo 92

Daiichi Sankyo Enters into Licensing Agreement with Cell Therapy 93

Daiichi Sankyo Enters into Licensing Agreement with MedImmune for FluMist 94

Dainippon Sumitomo Pharma Enters into Licensing Agreement with Daiichi Sankyo 95

Odonate Therapeutics Enters Into Licensing Agreement With Daiichi Sankyo 96

Affibody Enters Into Licensing Agreement With Daiichi Sankyo For Albumod 97

Daiichi Sankyo Invests in Cuorips 98

Daiichi Sankyo to Invest in USD196.7 Million in Luitpold Pharma 99

Daiichi Sankyo Raises USD3.6 Billion in Public Offering of Shares of Sun Pharma 100

Ambit Biosciences Completes Private Placement Of Shares For USD 25 Million 101

Ambit Biosciences Completes IPO Of Shares For USD 65 Million 102

Daiichi Sankyo to Raise USD713.4 Million in Public Offering of 0.81% 5th Series Bonds Due 2036 104

Daiichi Sankyo to Raise USD237.8 Million in Public Offering of 1.2% 6th Series Bonds Due 2046 105

Alfresa Pharma to Acquire 41 Products from Daiichi Sankyo 106

Amring Pharma Acquires Six ANDAs from Luitpold Pharma and AlphaForce 107

Egalet Acquires SPRIX Nasal Spray from Luitpold Pharma 108

CMIC CMO Completes Acquisition Of Research Equipment From Daiichi Sankyo 110

Sun Pharma Acquires Ranbaxy Labs for USD4 Billion 111

Daiichi Sankyo Acquires Majority Stake in Ambit Biosciences 114

Daiichi Sankyo Acquires Shanghai Xinshengyuan Pharma From Xinshengyuan Pharma 116

Daiichi Sankyo Plans To Acquire India-Based Pharma Company 117

Daiichi Sankyo Co Ltd, Key Competitors 118

Daiichi Sankyo Co Ltd, Key Employees 119

Daiichi Sankyo Co Ltd, Subsidiaries 121

Daiichi Sankyo Co Ltd, Joint Venture 124

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Daiichi Sankyo Co Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Daiichi Sankyo Company Ltd (Daiichi Sankyo) is a holding company that carries out the research, development, manufacture, and marketing of pharmaceutical products. The company offers a wide range of prescription drugs, over-the-counter (OTC) drugs, vaccines, and others. Its portfolio encompasses medicines for cardiovascular, neurological, nephrologic, diabetic, metabolic and infectious diseases; and various types of cancers. Daiichi Sankyo sells its products through its group companies, and an extensive network of medical representatives. It has operations in North America, South and Central America, Europe and Asia. Daiichi Sankyo is headquartered in Tokyo, Japan.

Daiichi Sankyo Co Ltd (4568)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 8

List of Figures 9

Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 11

Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 12

Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 13

Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 14

Daiichi Sankyo Co Ltd, Medical Devices Deals, 2012 to YTD 2018 16

Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 17

Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deal Details 23

Venture Financing 23

Ambit Biosciences Raises USD 25 Million In First Tranche Of Venture Financing 23

Ambit Biosciences Raises USD 7.07 Million In Venture Financing 25

Partnerships 26

Daiichi Sankyo Enters into Research Collaboration with Merck and Pfizer 26

Daiichi Sankyo Enters into Co-Development Agreement with Merck Sharp & Dohme 27

PhoreMost Enters into Collaboration Agreement with Plexxikon 28

Daiichi Sankyo Enters into Agreement with DarwinHealth 29

Evotec Enters into Agreement with U3 Pharma 30

Vernalis and Daiichi Sankyo Enter into Agreement 31

Daiichi Sankyo and Puma Biotech Enter into Research Agreement with Memorial Sloan Kettering Cancer Center 32

Daiichi Sankyo and Glycotope Enter into Option Agreement 33

Daiichi Sankyo Partners with Saitama Medical University 34

National Cancer Center, JVCKENWOOD, Sysmex and Daiichi Sankyo Enter into Agreement 35

University of Texas MD Anderson and Daiichi Sankyo Enter into Research Agreement 36

Bristol-Myers Squibb and Daiichi Sankyo Enter into Agreement 37

Daiichi Sankyo Enters into Agreement with Kyukyu Pharma 38

Daiichi Sankyo, Max Planck Innovation and Lead Discovery Center Enter into Research Agreement 39

ProLynx Enters into Partnership with Daiichi Sankyo 40

Daiichi Sankyo Enters into Research Agreement with Drugs for Neglected Diseases initiative 41

National Institutes of Biomedical Innovation, Daiichi Sankyo and Mitsubishi UFJ Capital Form Joint Venture 42

Daiichi Sankyo Enters into Research Agreement with Dana-Farber Cancer Institute 43

Daiichi Sankyo Enters into Research Agreement with Medicines for Malaria Venture 44

Daiichi Sankyo Enters into Research Agreement with AgonOx 45

Amgen and Daiichi Sankyo Enter into Agreement 46

Daiichi Sankyo Enters Into Marketing Agreement With Servier Canada 47

Astellas Pharm, Kyowa Hakko Kirin, Daiichi Sankyo, Eisai, Ono Pharma and Chugai Pharma to Enter into Agreemet with Four Research Institutions 48

Astellas Pharma, Daiichi Sankyo and Takeda Pharma Enter into Research Agreement 50

Asahikawa Medical University, Daiichi Sankyo and Mitsubishi UFJ Capital Form Joint Venture 51

Daiichi Sankyo Enters into Co-Marketing Agreement with Merck 52

Daiichi Sankyo Enters into Co-Marketing Agreement with Daewoong Pharma 53

Simcere Pharma Enters into Agreement with Daiichi Sankyo 54

Daiichi Sankyo, Japan Vaccine and Sanofi Enter into Co-Marketing Agreement 55

Daiichi Sankyo Partners with Cytoo 56

Biohit Enters into Distribution Agreement with Daiichi Sankyo 57

Daiichi Sankyo Enters into Agreement with Maruishi Pharma 58

Plexxikon Enters into Agreement with Merck 59

AstraZeneca Enters into Commercialization Agreement with Daiichi Sankyo for Movantik 60

Daiichi Sankyo Enters into Co-Marketing Agreement with UCB Biopharma for Lacosamide 61

Portola Pharma Enters into Expanded Agreement with Daiichi Sankyo 62

Sanford Burnham Enters into Co-Development Agreement with Daiichi Sankyo 63

MRC Technology Enters into Drug Discovery Agreement with Daiichi Sankyo 64

Agendia Enters into Co-Development Agreement with Daiichi Sankyo 65

Daiichi Sankyo Enters into Co-Promotion Agreement with Daewoong Pharma For Olostar 66

Daiichi Sankyo Enters Into Drug Discovery Agreement With Lead Discovery Center 67

Daiichi Sankyo Enters Into Co-Development Agreement With UCSF 68

Daiichi Sankyo and UMN Pharma Enter into Research Agreement for Norovirus Vaccine 69

Abcheck Enters Into Research Agreement With U3 Pharma 70

Daiichi Sankyo Forms Joint Venture With Innovation Network Corporation And Mitsubishi UFJ Capital 71

Daiichi Sankyo Enters Into Agreement With Amplimmune To Develop Therapy For Autoimmune Disease 72

PeptiDream Enters into Drug Discovery Agreement with Daiichi Sankyo 73

Daiichi Sankyo Venezuela Enters Into Co-Marketing Agreement With Ranbaxy Labs 74

Daiichi Sankyo Enters Into Co-Development Agreement With National Cancer Center Hospital East 75

Daiichi Sankyo Enters Into Co-Marketing Agreement With Terapia Ranbaxy For Sevikar 76

Daiichi Sankyo Enters Into Co-Development Agreement With NGM Biopharma For Diabetes Drugs 77

Mitsubishi Tanabe Pharma Expands its Co-Marketing Agreement with Daiichi Sankyo for MP-513 And TA-7284 78

Daiichi Sankyo And GlaxoSmithKline to Dissolve Joint Venture 79

Daiichi Sankyo Enters Into Co-Development Agreement With Terumo For Intradermal Vaccine 80

Merger 81

Daiichi Sankyo to Merge with Asubio Pharma 81

Licensing Agreements 82

Daiichi Sankyo Enters into Licensing Agreement with Glycotope 82

Menarini Enters into Licensing Agreement with Daiichi Sankyo 83

Daiichi Sankyo Enters into Licensing Agreement with Zymeworks 84

Daiichi Sankyo Enters into Licensing Agreement with Boston Pharma 85

Daiichi Sankyo to Enter into Licensing Agreement with Inspirion Delivery Sciences 86

Daiichi Sankyo Enters into Licensing Agreement with Sosei Group 87

Daiichi Sankyo Enters into Licensing Agreement with Heptares Therapeutics 88

Daiichi Sankyo Enters into Licensing Agreement with Kite Pharma 89

Daiichi Sankyo Enters into Licensing Agreement with Inspirion Delivery Sciences 90

Daiichi Sankyo Enters into Licensing Agreement with Zymeworks 91

Zymeworks Enters into Licensing Agreement with Daiichi Sankyo 92

Daiichi Sankyo Enters into Licensing Agreement with Cell Therapy 93

Daiichi Sankyo Enters into Licensing Agreement with MedImmune for FluMist 94

Dainippon Sumitomo Pharma Enters into Licensing Agreement with Daiichi Sankyo 95

Odonate Therapeutics Enters Into Licensing Agreement With Daiichi Sankyo 96

Affibody Enters Into Licensing Agreement With Daiichi Sankyo For Albumod 97

Equity Offering 98

Daiichi Sankyo Invests in Cuorips 98

Daiichi Sankyo to Invest in USD196.7 Million in Luitpold Pharma 99

Daiichi Sankyo Raises USD3.6 Billion in Public Offering of Shares of Sun Pharma 100

Ambit Biosciences Completes Private Placement Of Shares For USD 25 Million 101

Ambit Biosciences Completes IPO Of Shares For USD 65 Million 102

Debt Offering 104

Daiichi Sankyo to Raise USD713.4 Million in Public Offering of 0.81% 5th Series Bonds Due 2036 104

Daiichi Sankyo to Raise USD237.8 Million in Public Offering of 1.2% 6th Series Bonds Due 2046 105

Asset Transactions 106

Alfresa Pharma to Acquire 41 Products from Daiichi Sankyo 106

Amring Pharma Acquires Six ANDAs from Luitpold Pharma and AlphaForce 107

Egalet Acquires SPRIX Nasal Spray from Luitpold Pharma 108

CMIC CMO Completes Acquisition Of Research Equipment From Daiichi Sankyo 110

Acquisition 111

Sun Pharma Acquires Ranbaxy Labs for USD4 Billion 111

Daiichi Sankyo Acquires Majority Stake in Ambit Biosciences 114

Daiichi Sankyo Acquires Shanghai Xinshengyuan Pharma From Xinshengyuan Pharma 116

Daiichi Sankyo Plans To Acquire India-Based Pharma Company 117

Daiichi Sankyo Co Ltd-Key Competitors 118

Daiichi Sankyo Co Ltd-Key Employees 119

Daiichi Sankyo Co Ltd-Locations And Subsidiaries 121

Head Office 121

Other Locations & Subsidiaries 121

Joint Venture 124

Recent Developments 125

Strategy And Business Planning 125

Aug 01, 2018: Daiichi Sankyo transfers 41 products to Alfresa Pharma 125

Apr 27, 2018: Daiichi Sankyo to Reorganize Kitasato Daiichi Sankyo Vaccine into Specialized Manufacturing Subsidiary 126

Feb 23, 2018: Daiichi Sankyo Announces Organizational Restructuring Effective as of April 1, 2018 127

Jan 09, 2018: Daiichi Sankyo to Convert Kitasato Daiichi Sankyo Vaccine into Wholly Owned Subsidiary 129

Sep 07, 2017: Daiichi Sankyo Announces Organizational Restructuring Effective as of October 1, 2017 130

Feb 24, 2017: Daiichi Sankyo Announces Organizational Restructuring Effective as of April 1, 2017 131

Feb 15, 2017: Daiichi Sankyo Strengthens Authorized Generic Business through Daiichi Sankyo Espha 133

Feb 10, 2017: Daiichi Sankyo Announces Further Reorganization of its Research & Development Structure 135

Corporate Communications 136

May 11, 2018: Daiichi Sankyo Announces Changes to Representative Directors and Members of the Audit and Supervisory Board 136

Jan 31, 2017: Daiichi Sankyo Announces New Chairman and President 137

Legal and Regulatory 138

Jun 06, 2018: Daiichi Sankyo's U.S. Products Liability Litigation Settlement Program Moves Forward; More than 97 Percent of Eligible Litigants and Claimants Opt In 138

Mar 30, 2018: Daiichi Sankyo Agrees to Modify the Terms of the Settlement Program for U.S. Olmesartan Products Liability Litigation 139

Aug 01, 2017: Daiichi Sankyo Announces Settlement Agreement on U.S. Products Liability Litigation 140

Government and Public Interest 141

Jul 11, 2017: Daiichi Sankyo Selected for Ninth Consecutive Year as Constituent of FTSE4Good Global Index by FTSE Russell 141

Jul 03, 2017: 15th Takamine Memorial Daiichi Sankyo Prize Winner Announced 142

Jun 16, 2017: Daiichi Sankyos Japan Research Foundation for Clinical Pharmacology 10th Annual Clinical Pharmacology Research Award 143

Jan 18, 2017: Daiichi Sankyo Announces Participation in the Global Initiative, Access Accelerated 144

Product News 145

Oct 12, 2017: Daiichi Sankyo Announces Support from the Japan Agency for Medical Research and Developments CiCLE Program for Its Genetic Vaccine Platform, and Commencement of an Industry- Government-Academia Research & Development Collaboration for Development Vaccines Using the Platform 145

Oct 11, 2017: Astellas, Mitsubishi Tanabe Pharma, and Daiichi Sankyo Conduct JOINUS, a New Drug Discovery Program Using Drug-Repositioning Compound Library 146

09/03/2018: The FDA attributed the designation of innovative therapy to quizartinib, a FLT3 inhibitor for the treatment of relapsed / refractory AML from Daiichi Sankyo 147

08/30/2017: "Tazopipe Notice of additional adaptation acquisition of the blending static for the Note" Meiji 148

Aug 29, 2018: ProLynx and Daiichi Sankyo announce the development of technology for half-life extension of small molecules in the eye 149

08/29/2017: FDA Grants Breakthrough Therapy Designation to Daiichi Sankyos DS-8201 for HER2-Positive Metastatic Breast Cancer 150

08/01/2018: Daiichi Sankyo announce FDA grants breakthrough therapy designation to Daiichi Sankyos FLT3 inhibitor Quizartinib for relapsed/refractory FLT3-ITD AML 151

Jul 20, 2017: Daiichi Sankyo Opens Applications for Investigator-Initiated Studies Program 152

Jun 15, 2017: Daiichi Sankyo Launches New Generic Drugs through Its Daiichi Sankyo Espha Subsidiary 153

04/20/2018: Vaxart Announces $5 Million Inavir Revenue Milestone 156

Mar 30, 2017: Daiichi Sankyo Announces Collaborative Research on Drugs for Neglected Tropical Diseases 157

03/26/2018: Japanese Government to Stockpile Inavir Anti-influenza Drug for Combatting Pandemic Influenza Threats in Japan 158

Mar 16, 2017: The National Institutes of Biomedical Innovation, Health and Nutrition, Daiichi Sankyo,and Mitsubishi UFJ Capital Announce Open Innovation Research on New Cancer Immunotherapy 159

01/18/2017: - lactamase inhibitor formulated antibiotic formulation "Tazopipe Notice of additional indications and effect the acquisition of blending static for the Note" Meiji "" 160

01/18/2017: Daiichi Sankyo Initiates Phase 1/2 Study of Novel Antibody Drug Conjugate U3-1402 in Patients with HER3-Positive Metastatic or Unresectable Breast Cancer 161

Product Approvals 162

Feb 15, 2018: Daiichi Sankyo Submits Marketing Application for Mirogabalin in Japan 162

Clinical Trials 163

Jul 06, 2018: Northwestern University: Clinical Trial Show Promise in Leukemia 163

Jun 16, 2018: Phase 3 QuANTUM-R Study Demonstrates Daiichi Sankyos Quizartinib Significantly Prolongs Overall Survival as Single Agent Compared to Chemotherapy in Patients with Relapsed/Refractory AML with FLT3-ITD Mutations 164

Jun 12, 2018: EHA Late-Breaking, Plenary Presentation: Quizartinib Significantly Prolongs Overall Survival in Pivotal, Phase 3 AML Study 166

Jun 06, 2018: Daiichi Sankyo to Present Late-Breaking Phase 3 Data for Single Agent Quizartinib in Patients with Relapsed/Refractory AML with FLT3-ITD Mutations at Plenary Session at EHA 2018 167

May 08, 2018: Daiichi Sankyo Announces Single Agent Quizartinib Significantly Prolongs Overall Survival Compared with Chemotherapy in Patients with Relapsed/Refractory AML with FLT3-ITD Mutations (QuANTUM-R Study) 169

Dec 28, 2017: Odonate Therapeutics Announces Initiation of CONTESSA, a Phase 3 Study of Tesetaxel in Patients with Locally Advanced or Metastatic Breast Cancer 170

Dec 22, 2017: Glycotope Initiates Phase Ib Trial of Combination of Proprietary Anti-Tumor Antibodies 172

Dec 11, 2017: Daiichi Sankyo Presents Phase 1 Data for EZH1/2 Dual Inhibitor DS-3201 in Patients with Non-Hodgkin Lymphomas at the 59th Annual Meeting of the American Society of Hematology 173

Dec 07, 2017: Daiichi Sankyo Presents Updated Data for DS-8201 in Patients with HER2-Expressing Breast Cancer at San Antonio Breast Cancer Symposium 175

Nov 20, 2017: Daiichi Sankyo Initiates Pivotal Phase 2 Study of DS-8201 in Patients with HER2-Positive Advanced Gastric Cancer 176

Nov 14, 2017: Daiichi Sankyo Announces Presentation on its Investigational Agent DS-3201 at ASH 178

Nov 14, 2017: Daiichi Sankyo Announces Presentation on its Investigational Agent Quizartinib dihydrochloride at ASH 179

Nov 14, 2017: Daiichi Sankyo to Present Updated DS-8201 Data at SABCS 180

Sep 11, 2017: Daiichi Sankyo Presents New Data for DS-8201 in Multiple HER2-Expressing Solid Tumors at European Society for Medical Oncology (ESMO) 2017 Congress 181

Sep 06, 2017: Sanford Burnham Prebys and Daiichi Sankyo Announce Enrollment of First Subject in a Phase 1 Clinical Trial of DS-1211 in Healthy Volunteers 183

Aug 31, 2017: Daiichi Sankyo Announces Positive Top-line Results from Phase 3 Clinical Trial Evaluating Mirogabalin in Diabetic Peripheral Neuropathic Pain 184

Aug 31, 2017: Daiichi Sankyo Presents Data on DS-1205 at the European Society for Medical Oncology 2017 Congress 185

Aug 31, 2017: Daiichi Sankyo Showcases New Insights on DS-8201 at the European Society for Medical Oncology 2017 Congress 186

Aug 31, 2017: Daiichi Sankyo to Present Data on leukemia Drug Candidate Quizartinib at the European Society for Medical Oncology 2017 Congress 187

Aug 29, 2017: Daiichi Sankyo Initiates Pivotal Phase 2 Study of DS-8201 in Patients with HER2-Positive Metastatic Breast Cancer 188

Jun 30, 2017: Daiichi Sankyo Announces Top-line Results from Phase 3 Global Clinical Development Program Evaluating Mirogabalin in Pain Syndromes 189

Jun 05, 2017: New Precision Medicine Data on DS-8201 in HER2-Expressing Breast Cancer Revealed at 2017 American Society of Clinical Oncology (ASCO) Annual Meeting 191

Mar 29, 2017: Daiichi Sankyo Cancer Enterprise Showcases New Data on DS-8201 at American Association for Cancer Research 2017 Annual Meeting 193

Mar 29, 2017: Daiichi Sankyo Cancer Enterprise Showcases New Data on U3-1402 at American Association for Cancer Research 2017 Annual Meeting 194

Mar 29, 2017: Daiichi Sankyo Showcases New Data on EZH1/2 Inhibition at American Association for Cancer Research 2017 Annual Meeting 195

Other Significant Developments 196

Oct 09, 2018: Astellas, Mitsubishi Tanabe Pharma, and Daiichi Sankyo announce second public recruitment offering of "Joinus", a joint research program to discover new drugs using drug-repositioning compound library 196

Feb 28, 2018: Daiichi Sankyo Aligns U.S. Commercial Operations to Current Portfolio and Upcoming Cancer Pipeline 197

Oct 30, 2017: Daiichi Sankyo Working with Berkeley Lights' Beacon OptoFluidic Platform for Cell Line Development 198

Sep 26, 2017: Daiichi Sankyo Announces TaNeDS Global 2018 Collaborative Drug Discovery Program 199

Apr 27, 2017: Daiichi Sankyo Announces 15 Billion Yen Manufacturing Investment to Support Acceleration of Antibody Drug Conjugate Portfolio 201

Mar 23, 2017: Daiichi Sankyo to Facilitate New Drug Discovery in 2017 through Collaborative Research and Grants 202

Feb 14, 2017: PeptiDream Announces the Selection of Development Candidate from Discovery Collaboration with Daiichi Sankyo 203

Feb 02, 2017: Daiichi Sankyo Announces Continuation of Mobile Healthcare Field Clinic Service Aimed at Improving Healthcare Access in Tanzania 204

Jan 10, 2017: Daiichi Sankyo Announces Reorganization of Research & Development System 205

Appendix 206

Methodology 206

About GlobalData 206

Contact Us 206

Disclaimer 206


List Of Figure

List of Figures

Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 11

Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 12

Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 13

Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 14

Daiichi Sankyo Co Ltd, Medical Devices Deals, 2012 to YTD 2018 16


List Of Table

List of Tables

Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 11

Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 12

Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 13

Daiichi Sankyo Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 14

Daiichi Sankyo Co Ltd, Medical Devices Deals, 2012 to YTD 2018 16

Daiichi Sankyo Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 17

Ambit Biosciences Raises USD 25 Million In First Tranche Of Venture Financing 23

Ambit Biosciences Raises USD 7.07 Million In Venture Financing 25

Daiichi Sankyo Enters into Research Collaboration with Merck and Pfizer 26

Daiichi Sankyo Enters into Co-Development Agreement with Merck Sharp & Dohme 27

PhoreMost Enters into Collaboration Agreement with Plexxikon 28

Daiichi Sankyo Enters into Agreement with DarwinHealth 29

Evotec Enters into Agreement with U3 Pharma 30

Vernalis and Daiichi Sankyo Enter into Agreement 31

Daiichi Sankyo and Puma Biotech Enter into Research Agreement with Memorial Sloan Kettering Cancer Center 32

Daiichi Sankyo and Glycotope Enter into Option Agreement 33

Daiichi Sankyo Partners with Saitama Medical University 34

National Cancer Center, JVCKENWOOD, Sysmex and Daiichi Sankyo Enter into Agreement 35

University of Texas MD Anderson and Daiichi Sankyo Enter into Research Agreement 36

Bristol-Myers Squibb and Daiichi Sankyo Enter into Agreement 37

Daiichi Sankyo Enters into Agreement with Kyukyu Pharma 38

Daiichi Sankyo, Max Planck Innovation and Lead Discovery Center Enter into Research Agreement 39

ProLynx Enters into Partnership with Daiichi Sankyo 40

Daiichi Sankyo Enters into Research Agreement with Drugs for Neglected Diseases initiative 41

National Institutes of Biomedical Innovation, Daiichi Sankyo and Mitsubishi UFJ Capital Form Joint Venture 42

Daiichi Sankyo Enters into Research Agreement with Dana-Farber Cancer Institute 43

Daiichi Sankyo Enters into Research Agreement with Medicines for Malaria Venture 44

Daiichi Sankyo Enters into Research Agreement with AgonOx 45

Amgen and Daiichi Sankyo Enter into Agreement 46

Daiichi Sankyo Enters Into Marketing Agreement With Servier Canada 47

Astellas Pharm, Kyowa Hakko Kirin, Daiichi Sankyo, Eisai, Ono Pharma and Chugai Pharma to Enter into Agreemet with Four Research Institutions 48

Astellas Pharma, Daiichi Sankyo and Takeda Pharma Enter into Research Agreement 50

Asahikawa Medical University, Daiichi Sankyo and Mitsubishi UFJ Capital Form Joint Venture 51

Daiichi Sankyo Enters into Co-Marketing Agreement with Merck 52

Daiichi Sankyo Enters into Co-Marketing Agreement with Daewoong Pharma 53

Simcere Pharma Enters into Agreement with Daiichi Sankyo 54

Daiichi Sankyo, Japan Vaccine and Sanofi Enter into Co-Marketing Agreement 55

Daiichi Sankyo Partners with Cytoo 56

Biohit Enters into Distribution Agreement with Daiichi Sankyo 57

Daiichi Sankyo Enters into Agreement with Maruishi Pharma 58

Plexxikon Enters into Agreement with Merck 59

AstraZeneca Enters into Commercialization Agreement with Daiichi Sankyo for Movantik 60

Daiichi Sankyo Enters into Co-Marketing Agreement with UCB Biopharma for Lacosamide 61

Portola Pharma Enters into Expanded Agreement with Daiichi Sankyo 62

Sanford Burnham Enters into Co-Development Agreement with Daiichi Sankyo 63

MRC Technology Enters into Drug Discovery Agreement with Daiichi Sankyo 64

Agendia Enters into Co-Development Agreement with Daiichi Sankyo 65

Daiichi Sankyo Enters into Co-Promotion Agreement with Daewoong Pharma For Olostar 66

Daiichi Sankyo Enters Into Drug Discovery Agreement With Lead Discovery Center 67

Daiichi Sankyo Enters Into Co-Development Agreement With UCSF 68

Daiichi Sankyo and UMN Pharma Enter into Research Agreement for Norovirus Vaccine 69

Abcheck Enters Into Research Agreement With U3 Pharma 70

Daiichi Sankyo Forms Joint Venture With Innovation Network Corporation And Mitsubishi UFJ Capital 71

Daiichi Sankyo Enters Into Agreement With Amplimmune To Develop Therapy For Autoimmune Disease 72

PeptiDream Enters into Drug Discovery Agreement with Daiichi Sankyo 73

Daiichi Sankyo Venezuela Enters Into Co-Marketing Agreement With Ranbaxy Labs 74

Daiichi Sankyo Enters Into Co-Development Agreement With National Cancer Center Hospital East 75

Daiichi Sankyo Enters Into Co-Marketing Agreement With Terapia Ranbaxy For Sevikar 76

Daiichi Sankyo Enters Into Co-Development Agreement With NGM Biopharma For Diabetes Drugs 77

Mitsubishi Tanabe Pharma Expands its Co-Marketing Agreement with Daiichi Sankyo for MP-513 And TA-7284 78

Daiichi Sankyo And GlaxoSmithKline to Dissolve Joint Venture 79

Daiichi Sankyo Enters Into Co-Development Agreement With Terumo For Intradermal Vaccine 80

Daiichi Sankyo to Merge with Asubio Pharma 81

Daiichi Sankyo Enters into Licensing Agreement with Glycotope 82

Menarini Enters into Licensing Agreement with Daiichi Sankyo 83

Daiichi Sankyo Enters into Licensing Agreement with Zymeworks 84

Daiichi Sankyo Enters into Licensing Agreement with Boston Pharma 85

Daiichi Sankyo to Enter into Licensing Agreement with Inspirion Delivery Sciences 86

Daiichi Sankyo Enters into Licensing Agreement with Sosei Group 87

Daiichi Sankyo Enters into Licensing Agreement with Heptares Therapeutics 88

Daiichi Sankyo Enters into Licensing Agreement with Kite Pharma 89

Daiichi Sankyo Enters into Licensing Agreement with Inspirion Delivery Sciences 90

Daiichi Sankyo Enters into Licensing Agreement with Zymeworks 91

Zymeworks Enters into Licensing Agreement with Daiichi Sankyo 92

Daiichi Sankyo Enters into Licensing Agreement with Cell Therapy 93

Daiichi Sankyo Enters into Licensing Agreement with MedImmune for FluMist 94

Dainippon Sumitomo Pharma Enters into Licensing Agreement with Daiichi Sankyo 95

Odonate Therapeutics Enters Into Licensing Agreement With Daiichi Sankyo 96

Affibody Enters Into Licensing Agreement With Daiichi Sankyo For Albumod 97

Daiichi Sankyo Invests in Cuorips 98

Daiichi Sankyo to Invest in USD196.7 Million in Luitpold Pharma 99

Daiichi Sankyo Raises USD3.6 Billion in Public Offering of Shares of Sun Pharma 100

Ambit Biosciences Completes Private Placement Of Shares For USD 25 Million 101

Ambit Biosciences Completes IPO Of Shares For USD 65 Million 102

Daiichi Sankyo to Raise USD713.4 Million in Public Offering of 0.81% 5th Series Bonds Due 2036 104

Daiichi Sankyo to Raise USD237.8 Million in Public Offering of 1.2% 6th Series Bonds Due 2046 105

Alfresa Pharma to Acquire 41 Products from Daiichi Sankyo 106

Amring Pharma Acquires Six ANDAs from Luitpold Pharma and AlphaForce 107

Egalet Acquires SPRIX Nasal Spray from Luitpold Pharma 108

CMIC CMO Completes Acquisition Of Research Equipment From Daiichi Sankyo 110

Sun Pharma Acquires Ranbaxy Labs for USD4 Billion 111

Daiichi Sankyo Acquires Majority Stake in Ambit Biosciences 114

Daiichi Sankyo Acquires Shanghai Xinshengyuan Pharma From Xinshengyuan Pharma 116

Daiichi Sankyo Plans To Acquire India-Based Pharma Company 117

Daiichi Sankyo Co Ltd, Key Competitors 118

Daiichi Sankyo Co Ltd, Key Employees 119

Daiichi Sankyo Co Ltd, Subsidiaries 121

Daiichi Sankyo Co Ltd, Joint Venture 124

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Daiichi Sankyo Co Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.